Phase II Trial of Hypomethylating Agent Combined with Nivolumab for Acute Myeloid Leukaemia Relapse After Allogeneic Haematopoietic Cell Transplantation - Immune Signature Correlates with Response

by Petya Apostolova, Stefanie Kreutmair, Cristina Toffalori, Marco Punta, Susanne Unger, Ann-Cathrin Burk, Claudia Wehr, Kristina Maas-Bauer, Wolfgang Melchinger, Eileen Haring, Rouven Höfflin, Khalid Shoumariyeh, Valerie Hupfer, Eliza Maria Lauer, Sandra Duquesne, Theresa Lowinus, Matthias Weiß, Caroline Böke, Dietmar Pfeifer, Reinhard Marks, Hartmut Bertz, Ralph Wäsch, Gabriele Ihorst, Justus Duyster, Melanie Börries, Andrieux Geoffroy, Jürgen Finke, Burkhard Becher, Luca Vago, Robert Zeiser · 2023